Philippines FDA approves first ever generic version of Pfizer anti-Covid pill

Read Time:1 Minute, 54 Second

Manila (Philippines), January 25: The Philippines Food and Drug Administration (FDA) has approved the world’s first generic version of Pfizer’s anti-Coronavirus pill Paxlovid, just days after the original was granted Emergency Use Authorisation (EUA) by the US FDA.

The Philippines FDA has approved the department of health’s application for a compassionate special permit application for the first generic version of Paxlovid that has been launched by Beximco Pharmaceuticals, a leading generic drugmaker from Bangladesh.

Philippines-based Pharmaceutical company Biocare Lifesciences Inc would be the distributor and importer of a generic drug, which would be sold under the brand name Bexovid in the Philippines.

According to Pfizer, the risk of hospitalisation or death is reduced by 89% when Paxlovid is given within three days of the onset of symptoms and by 88% when given within five days of the onset of symptoms. The treatment, a combination of Nirmatrelvir and Ritonavir tablets, is given together twice a day for five days and is recommended for treatment of mild to moderate cases of Covid-19.

Pfizer data also suggests the drug remains effective against the faster-spreading Omicron variant of the Coronavirus, which is driving the latest surge in Covid-19 cases globally.

“The approval by the Philippines FDA will make Bexovid accessible to Covid-19 patients in the country and add another treatment protocol to the existing drugs. We plan to import 20,000 to 30,000 courses of Bexovid initially and expect the supplies to begin in the first week of February. Bexovid is expected to be priced 50-60% cheaper than the original Pfizer drug, making it an affordable option,” said Dileep Tiwari, Managing Director, Biocare Lifesciences, during an interview with CNN.

Bexovid is recommended as an at-home treatment to help reduce the severity of the infection. The drug has the potential to eliminate many hospitalizations, thus helping reduce the strain on the healthcare infrastructure.

“Bexovid is not meant for patients who are hospitalised. Any patient who is Covid-19 positive can buy the drug from hospitals once supplies begin,” said Mr. Tiwari in a CNN interview.

Separately, Bangladesh’s Directorate General of Drug Administration has also granted EUA for Bexovid to treat mild-to-moderate Covid-19 cases in patients aged 12 and above.

The post Philippines FDA approves first ever generic version of Pfizer anti-Covid pill appeared first on Republic News Today.

World

British Parliament Hosts First Pre-Navratri Awards Ceremony with Shri Rajrajeshwar Guruji and Other Distinguished Members

London [UK], September 3: On Monday, September 2nd, following the Summer recess of the British Parliament, a remarkable event took place to mark the first Pre-Navratri celebration and present awards to 21 distinguished members, including esteemed saints Bhakti Swarup Sanyasi Maharaj and Pandit Gaurangi Gauri Ji. Organized by the International Siddhashram Shakti Centre UK and […]

Read More
World

Indian Achievers’ Forum in association with CSR Times hosts annual conclave in Goa, CM Sawant calls for greater participation

Panjim (Goa) [India] August 30: The National Conclave on Indian Achievers’ Awards by Indian Achievers’ Forum and the 11th Corporate Social Responsibility Summit and CSR Times Awards 2024 were held in Goa on Friday, 23rd August, at the prestigious Raj Bhawan, Goa. The summit was organized by the Indian Achievers’ Forum in association with CSR […]

Read More
World

Ashoka Group of Schools Becomes First in India to Participate in UN Event in Geneva

Nashik (Maharashtra) [India], August 29: Demonstrating its commitment to providing unparalleled global exposure, the Ashoka Group of Schools recently organized an Education and Knowledge Exchange tour to Geneva, Switzerland and Lyon, France, for its 16 students from grades 9-12. Accompanied by Ashoka educators Dr Dinesh Sabnis and Ms Simar Ahluwalia, these students participated in the […]

Read More